S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

Atara Biotherapeutics News Headlines (NASDAQ:ATRA)

$13.52
-1.24 (-8.40 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$13.23
Now: $13.52
$15.05
50-Day Range
$13.18
MA: $14.82
$17.79
52-Week Range
$10.38
Now: $13.52
$41.97
Volume1.31 million shs
Average Volume644,743 shs
Market Capitalization$732.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

Headlines

Atara Biotherapeutics (NASDAQ ATRA) News Headlines

Source:
DateHeadline
Atara Biotherapeutics to Participate at Two Upcoming Investor ConferencesAtara Biotherapeutics to Participate at Two Upcoming Investor Conferences
finance.yahoo.com - February 20 at 6:33 PM
Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on ThursdayAtara Biotherapeutics (ATRA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - February 20 at 9:53 AM
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
finance.yahoo.com - February 19 at 5:23 PM
Atara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Canaccord GenuityAtara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - February 18 at 7:43 AM
Insider Selling: Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO Sells 1,781 Shares of StockInsider Selling: Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO Sells 1,781 Shares of Stock
www.americanbankingnews.com - February 10 at 9:02 PM
Atara Biotherapeutics Inc (NASDAQ:ATRA) Insider Joe Newell Sells 4,117 SharesAtara Biotherapeutics Inc (NASDAQ:ATRA) Insider Joe Newell Sells 4,117 Shares
www.americanbankingnews.com - February 10 at 9:02 PM
Atara Biotherapeutics (NASDAQ:ATRA) vs. Amgen (NASDAQ:AMGN) Head to Head AnalysisAtara Biotherapeutics (NASDAQ:ATRA) vs. Amgen (NASDAQ:AMGN) Head to Head Analysis
www.americanbankingnews.com - February 10 at 10:32 AM
Zacks: Analysts Anticipate Atara Biotherapeutics Inc (NASDAQ:ATRA) to Announce -$1.30 EPSZacks: Analysts Anticipate Atara Biotherapeutics Inc (NASDAQ:ATRA) to Announce -$1.30 EPS
www.americanbankingnews.com - February 6 at 10:16 PM
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial OfficerAtara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
finance.yahoo.com - February 5 at 8:40 AM
Head to Head Review: Atara Biotherapeutics (NASDAQ:ATRA) vs. Surface Oncology (NASDAQ:SURF)Head to Head Review: Atara Biotherapeutics (NASDAQ:ATRA) vs. Surface Oncology (NASDAQ:SURF)
www.americanbankingnews.com - February 3 at 12:55 PM
Atara Biotherapeutics Inc (NASDAQ:ATRA) Given Average Rating of "Hold" by AnalystsAtara Biotherapeutics Inc (NASDAQ:ATRA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 1 at 11:52 AM
5 Beaten-Down Biotech Stocks Set to Rebound in 20205 Beaten-Down Biotech Stocks Set to Rebound in 2020
finance.yahoo.com - December 18 at 8:59 AM
Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc (ATRA)Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc (ATRA)
finance.yahoo.com - December 11 at 11:28 PM
Atara Biotherapeutics (ATRA) Presents At 2019 ASH Annual Meeting - SlideshowAtara Biotherapeutics (ATRA) Presents At 2019 ASH Annual Meeting - Slideshow
seekingalpha.com - December 11 at 1:23 PM
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual MeetingAtara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - December 9 at 10:52 AM
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx ConferenceAtara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
finance.yahoo.com - November 26 at 7:31 PM
Turnaround In Progress: Key Takeaways From Atara Biotherapeutics Q3 Earnings CallTurnaround In Progress: Key Takeaways From Atara Biotherapeutics' Q3 Earnings Call
seekingalpha.com - November 14 at 1:54 PM
Atara Biotherapeutics (ATRA) Upgraded to Buy: Heres WhyAtara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
www.nasdaq.com - November 12 at 1:53 PM
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's WhyAtara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
finance.yahoo.com - November 12 at 1:53 PM
Edited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMTEdited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMT
finance.yahoo.com - November 8 at 9:12 AM
Atara Biotherapeutics Inc (ATRA) Q3 2019 Earnings Call TranscriptAtara Biotherapeutics Inc (ATRA) Q3 2019 Earnings Call Transcript
www.fool.com - November 8 at 7:56 AM
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic ProgressAtara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
finance.yahoo.com - November 7 at 7:54 AM
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual MeetingAtara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 6 at 9:38 AM
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
finance.yahoo.com - October 30 at 5:34 PM
Atara Biotherapeutics (ATRA) Presents at Cell & Gene Meeting On The Mesa - SlideshowAtara Biotherapeutics (ATRA) Presents at Cell & Gene Meeting On The Mesa - Slideshow
seekingalpha.com - October 3 at 9:18 PM
Atara Biotherapeutics: Current Price Presents Enticing OpportunitiesAtara Biotherapeutics: Current Price Presents Enticing Opportunities
seekingalpha.com - October 2 at 11:23 AM
Atara Biotherapeutics Stock Falls After Goldman DowngradeAtara Biotherapeutics Stock Falls After Goldman Downgrade
finance.yahoo.com - September 27 at 3:08 PM
ATRA Stock Hits Five-Year Low on Goldman Bear NoteATRA Stock Hits Five-Year Low on Goldman Bear Note
finance.yahoo.com - September 27 at 3:08 PM
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Invest In Growth?Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Invest In Growth?
finance.yahoo.com - September 26 at 3:25 PM
ATRA.O - Atara Biotherapeutics Inc Profile | ReutersATRA.O - Atara Biotherapeutics Inc Profile | Reuters
www.reuters.com - September 25 at 8:32 PM
3 Biotech Stocks Surging on Positive Results3 Biotech Stocks Surging on Positive Results
finance.yahoo.com - September 23 at 7:15 AM
3 Biotech Stocks Surging on Positive Results3 Biotech Stocks Surging on Positive Results
finance.yahoo.com - September 23 at 7:15 AM
Atara Biotherapeutics Reports Early Findings of...Atara Biotherapeutics Reports Early Findings of...
www.benzinga.com - September 13 at 5:29 PM
Atara T-cell therapy shows encouraging action in early-stage MS studyAtara T-cell therapy shows encouraging action in early-stage MS study
seekingalpha.com - September 13 at 5:29 PM
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
finance.yahoo.com - September 10 at 6:12 AM
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech ConferenceAtara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
finance.yahoo.com - August 29 at 11:43 AM
Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?
finance.yahoo.com - August 28 at 12:39 PM
Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMTEdited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT
finance.yahoo.com - August 12 at 12:58 PM
BRIEF-Atara Biotherapeutics Reports Q2 Loss Per Share $1.60BRIEF-Atara Biotherapeutics Reports Q2 Loss Per Share $1.60
www.msn.com - August 9 at 1:11 AM
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call TranscriptAtara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 1:11 AM
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational ProgressAtara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
finance.yahoo.com - August 8 at 11:24 AM
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call onAtara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on
www.nasdaq.com - August 1 at 11:44 PM
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
finance.yahoo.com - August 1 at 11:44 PM
Atara Bio pries $150M stock offeringAtara Bio pries $150M stock offering
seekingalpha.com - July 19 at 5:46 PM
Atara Bio prices $150M stock offeringAtara Bio prices $150M stock offering
seekingalpha.com - July 19 at 10:07 AM
Atara Biotherapeutics Announces Pricing of $150.0 Million Public OfferingAtara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
finance.yahoo.com - July 19 at 10:07 AM
Atara launches $125M stock offering; shares down 2% after hoursAtara launches $125M stock offering; shares down 2% after hours
seekingalpha.com - July 18 at 6:41 PM
Atara to initiate U.S. application for tab-cel in H2 2020Atara to initiate U.S. application for tab-cel in H2 2020
seekingalpha.com - July 16 at 9:07 AM
Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next YearAtara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
finance.yahoo.com - July 16 at 9:07 AM
Why Atara Biotherapeutics Has Slumped in 2019Why Atara Biotherapeutics Has Slumped in 2019
finance.yahoo.com - July 9 at 8:50 AM
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel